The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Celldex; Merck
Honoraria - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Merck; Merck; Pieris Pharmaceuticals; Roche
Consulting or Advisory Role - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Merck; Merck; Pieris Pharmaceuticals; Roche
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lion Biotechnologies; Merck; Merck; Pieris Pharmaceuticals; Roche
 
Scott Joseph Antonia
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb
 
Suzanne Louise Topalian
Stock and Other Ownership Interests - Aduro Biotech (I); Compugen (I); Jounce Therapeutics (I); Neximmune (I); Potenza Therapeutics (I)
Consulting or Advisory Role - Amgen (I); Five Prime Therapeutics; Five Prime Therapeutics (I); GlaxoSmithKline; GlaxoSmithKline (I); Jounce Therapeutics; Jounce Therapeutics (I); MedImmune (I); Merck (I); Pfizer (I); Potenza Therapeutics (I); Sanofi; Sanofi (I)
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb (I); Compugen (I); Potenza Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Aduro Biotech (I); Bristol-Myers Squibb (I); Potenza Therapeutics (I)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Sanofi
 
Dirk Schadendorf
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche Pharma AG
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche Pharma AG
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche Pharma AG
Research Funding - MSD (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche Pharma AG
 
James M. G. Larkin
Research Funding - Novartis (Inst); Pfizer (Inst)
 
Mario Sznol
Consulting or Advisory Role - Amgen; Anaeropharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Immune Design; Kyowa Hakko Kirin; Lion Biotechnologies; Merus; Nektar; Symphony Evolution
Other Relationship - Haymarket Media
 
Helen Y Liu
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Ian Waxman
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Caroline Robert
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche Pharma AG
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche Pharma AG